Retension Pharmaceuticals (NASDAQ:RTSN) Stock Moved Down to "Sell" by Wall Street Zen

Retension Pharmaceuticals logo with background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded Retension Pharmaceuticals from “hold” to “sell.” Other analysts are more positive: the stock has a consensus “buy” rating and an average price target of $52.50.
  • RTSN opened at $10.51, within its 12-month range of $9.23 to $18.64. The company reported a quarterly loss of $7.33 per share, and analysts expect a full-year loss of $7.08 per share.
  • CEO Eric Keller and Director Franklin Berger each bought shares at $12.00 in October, purchasing 20,800 and 10,000 shares, respectively.
  • Five stocks to consider instead of Retension Pharmaceuticals.

Retension Pharmaceuticals (NASDAQ:RTSN - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Sunday, Wall Street Zen reports.

Other equities research analysts also recently issued research reports about the stock. Oppenheimer started coverage on shares of Retension Pharmaceuticals in a research note on Tuesday, November 3rd. They set an "outperform" rating and a $50.00 price target on the stock. Zacks Research assumed coverage on shares of Retension Pharmaceuticals in a research note on Wednesday, November 4th. They issued a "hold" rating for the company. Leerink Partners started coverage on shares of Retension Pharmaceuticals in a report on Tuesday, November 3rd. They set a "strong-buy" rating for the company. Finally, Guggenheim started coverage on shares of Retension Pharmaceuticals in a research report on Monday, November 2nd. They set a "buy" rating and a $55.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $52.50.

View Our Latest Report on RTSN

Retension Pharmaceuticals Stock Performance

RTSN stock opened at $10.51 on Friday. Retension Pharmaceuticals has a 12 month low of $9.23 and a 12 month high of $18.64.

Retension Pharmaceuticals (NASDAQ:RTSN - Get Free Report) last released its earnings results on Wednesday, November 18th. The company reported ($7.33) earnings per share for the quarter. On average, sell-side analysts expect that Retension Pharmaceuticals will post -7.08 EPS for the current fiscal year.

Insider Activity at Retension Pharmaceuticals

In other Retension Pharmaceuticals news, CEO Eric Keller bought 20,800 shares of Retension Pharmaceuticals stock in a transaction dated Tuesday, October 13th. The shares were acquired at an average cost of $12.00 per share, with a total value of $249,600.00. Following the acquisition, the chief executive officer directly owned 423,377 shares of the company's stock, valued at $5,080,524. The trade was a 5.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Franklin Berger bought 10,000 shares of Retension Pharmaceuticals stock in a transaction dated Tuesday, October 13th. The stock was acquired at an average cost of $12.00 per share, for a total transaction of $120,000.00. Following the completion of the acquisition, the director directly owned 10,000 shares in the company, valued at $120,000. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Retension Pharmaceuticals Company Profile

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Retension Pharmaceuticals Right Now?

Before you consider Retension Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Retension Pharmaceuticals wasn't on the list.

While Retension Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines